TCR up­start an­nounces CEO ex­it, with CSO now act­ing re­place­ment

A pub­lic T cell biotech’s chief ex­ec­u­tive has de­cid­ed to leave the com­pa­ny.

TScan Ther­a­peu­tics said Fri­day morn­ing that CEO David South­well stepped down ear­li­er this week, leav­ing both his chief ex­ec­u­tive and board mem­ber roles. Fill­ing in is Gavin MacBeath, the com­pa­ny’s CSO and COO. He be­came the act­ing CEO on Tues­day, and will con­tin­ue to re­main CSO and COO, TScan’s an­nounce­ment read.

South­well didn’t re­veal what his next steps are, say­ing in pre­pared re­marks on­ly that he looks for­ward to fol­low­ing the com­pa­ny as “I move on to oth­er op­por­tu­ni­ties.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN